<DOC>
	<DOCNO>NCT01660477</DOCNO>
	<brief_summary>The purpose two part study assess effect multiple dose isavuconazole pharmacokinetics multiple dos lopinavir/ritonavir effect multiple dose lopinavir/ritonavir pharmacokinetics isavuconazole . Part 1 study include 12 subject randomize receive either isavuconazole alone isavuconazole combination lopinavir/ritonavir . The purpose Part 1 evaluate safety tolerability establish effect multiple dos lopinavir/ritonavir isavuconazole . Part 2 , initiate , include 54 subject randomize receive isavuconazole alone , lopinavir/ritonavir alone , isavuconazole combination lopinavir/ritonavir .</brief_summary>
	<brief_title>Drug-drug Interaction Study Between Lopinavir/Ritonavir Isavuconazole</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>The subject body weight least 45 kg body mass index ( BMI ) 18 32 kg/m2 , inclusive Results aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) , total bilirubin , lipase , amylase , glucose triglyceride must within normal range The female subject agree sexual abstinence , surgically sterile , postmenopausal ( define least 2 year Screening without menses ) , use medically acceptable double barrier method ( e.g . spermicide diaphragm , spermicide condom ) prevent pregnancy agree continue use method Screening 3 week followup visit end study ; lactate pregnant document negative pregnancy test Screening Day 1 The male subject agree sexual abstinence , surgically sterile , use medically acceptable method prevent pregnancy agree continue use method Screening 3 week followup visit end study The subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease , family history Long QT syndrome ( suggest sudden death close relative young age due possible probable cardiac cause ) The subject history pancreatitis The subject positive result hepatitis C antibody , hepatitis B surface antigen Screening know positive human immunodeficiency virus ( HIV ) The subject know suspect allergy component trial product include lopinavir/ritonavir azole class compound , history multiple and/or severe allergy drug food ( judge investigator ) , history severe anaphylactic reaction The subject smoker ( use tobacco nicotine containing product ) within 6 month prior Screening The subject treatment prescription drug complementary alternative medicine within 14 day prior Day 1 , overthecounter medication within 1 week prior Day 1 , exception acetaminophen 2 g/day The subject recent history ( within last 2 year ) drug alcohol abuse , define investigator , positive drug and/or alcohol screen The subject participate previous isavuconazole study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Isavuconazole</keyword>
	<keyword>Lopinavir/ritonavir</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>BAL8557</keyword>
	<keyword>Kaletra Â®</keyword>
</DOC>